• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

RCT Results: Does Dexamethasone Prevent Neonatal Adverse Outcomes in Low-Resource Settings?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • WHO ACTION Trial Collaborators (Lancet eClinicalMedicine, 2022) assessed the safety and efficacy of dexamethasone when given to women at risk of late preterm birth in hospitals in low-resource countries 

METHODS: 

  • Double-blind, randomized trial 
    • 4 hospitals in India (December 2017 to May 2020) 
  • Participants 
    • Pregnant women at risk of preterm birth between 34w0d and 36w0d  
    • Birth planned or expected in the next 48 hours  
  • Interventions  
    • Dexamethasone IM 6 mg injection every 12 hours with a maximum of four doses or until hospital discharge or birth (whichever came first) 
    • Placebo 
  • Primary outcomes 
    • Neonatal death 
    • Any baby death (stillbirth or neonatal death) 
    • Severe neonatal respiratory distress 
    • Possible maternal bacterial infection 

RESULTS: 

  • Dexamethasone: 391 participants | Placebo: 391 participants
  • Between the two groups, there was no difference in risk of  
    • Neonatal death  
      • Dexamethasone: 2.7% 
      • Placebo: 2.8%  
      • RR 0.95 (95% CI, 0.42 to 2.12) 
    • Any baby death 
      • Dexamethasone: 3.8% 
      • Placebo: 4.4% 
      • RR 0.87 (95% CI, 0.45 to 1.67) 
  • There was also no difference in  
    • Severe neonatal respiratory distress 
      • Dexamethasone: 0.8% 
      • Placebo: 0.5% 
      • RR 1.56 (95% CI, 0.26 to 9.29) 
    • Possible maternal bacterial infection 
      • Dexamethasone: 2.3% 
      • Placebo: 3.8%  
      • RR 0.60 (95% CI, 0.27 to 1.35) 
  • Fewer neonates in the dexamethasone group required resuscitation at birth 
    • RR 0.38 (95% CI, 0.15 to 0.97) 
  • The trial was stopped due to lower-than-expected prevalence of primary outcomes and slow recruitment 
    • Planned on 8% neonatal mortality | Actual mortality 2.7% 

CONCLUSION: 

  • There was no difference in risk of neonatal death or respiratory distress with dexamethasone in this setting 
  • Reason for lack of benefit compared to ALPS study aside from sample size may be related to dosing 
    • ALPS regimen was 12 mg betamethasone or placebo 24 hours apart  
    • In both trials, a substantial proportion of women only received a single dose  
  • The authors state 

…the use of major resuscitation at birth for newborns was significantly lower with dexamethasone 

the overall trend of effects suggests that potential benefit of dexamethasone in late preterm cannot be excluded, and further trials are required 

Learn More – Primary Sources: 

Antenatal dexamethasone for late preterm birth: A multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial 

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

WHO ACTION RCT Outcomes: Dexamethasone and Risk of Neonatal Death in Women from Low-Income Countries at Risk for Preterm Birth
Antenatal Corticosteroids – When to Administer?
Antenatal Corticosteroids Plus Magnesium Sulfate in Extreme Preterm: Neurodevelopmental Outcomes
Cochrane Update: Antenatal Corticosteroids and Impact on Respiratory Morbidity or Death in Preterm Births
SMFM Issues Guidance on Antenatal Corticosteroid Use and Late Preterm Delivery

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site